Maxygen Company Description
Maxygen dedicates itself to maximizing the potential of protein-based pharmaceuticals. The development-stage biotechnology company is creating improved versions of proven protein compounds to treat serious diseases, such as neutropenia, or the low white blood cell count often caused by chemotherapy treatments. The company's lead candidate MAXY-G34 (for neutropenia) is in early stage clinical trials; it is a bio-engineered version of a natural protein that stimulates the production of white blood cells. Maxygen has other candidates at preclinical stages of development that may treat rheumatoid arthritis and other conditions.
View the Comprehensive Company Description for Maxygen
The Company Description provides a historical perspective of Maxygen's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Maxygen's evolution in the marketplace.
